Total Payments
$268,741
2024 Payments
$57,566
Companies
11
Transactions
150
Medicare Patients
2,905
Medicare Billing
$495,165
Payment Breakdown by Category
Consulting$119,627 (44.5%)
Travel$65,366 (24.3%)
Research$50,770 (18.9%)
Other$30,468 (11.3%)
Food & Beverage$2,511 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $119,627 | 33 | 44.5% |
| Travel and Lodging | $65,366 | 39 | 24.3% |
| Unspecified | $50,770 | 36 | 18.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,468 | 18 | 11.3% |
| Food and Beverage | $2,511 | 24 | 0.9% |
Payments by Type
General
$217,971
114 transactions
Research
$50,770
36 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $131,749 | 78 | $0 (2024) |
| Novo Nordisk AS | $45,514 | 11 | $0 (2023) |
| Alnylam Pharmaceuticals Inc. | $41,371 | 35 | $0 (2024) |
| Genentech, Inc. | $13,600 | 2 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $12,845 | 3 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $7,977 | 8 | $0 (2024) |
| Akcea Therapeutics, Inc. | $5,393 | 3 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $5,265 | 2 | $0 (2021) |
| Medtronic Vascular, Inc. | $2,925 | 5 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $1,879 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $57,566 | 36 | PFIZER INC. ($40,318) |
| 2023 | $55,463 | 24 | Novo Nordisk AS ($21,141) |
| 2022 | $67,171 | 30 | PFIZER INC. ($33,135) |
| 2021 | $20,533 | 11 | PFIZER INC. ($5,740) |
| 2020 | $12,890 | 10 | PFIZER INTERNATIONAL LLC ($12,890) |
| 2019 | $25,406 | 20 | Alnylam Pharmaceuticals Inc. ($11,330) |
| 2018 | $26,845 | 14 | PFIZER INC. ($19,933) |
| 2017 | $2,869 | 5 | Medtronic Vascular, Inc. ($2,772) |
All Payment Transactions
150 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | VYNDAMAX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/30/2024 | PFIZER INC. | VYNDAQEL (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: VYNDAQEL CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 12/19/2024 | PFIZER INC. | VYNDAQEL (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: VYNDAQEL CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 11/13/2024 | PFIZER INC. | VYNDAMAX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/08/2024 | PFIZER INC. | VYNDAMAX (Drug) | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/05/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,520.00 | General |
| 11/04/2024 | PFIZER INC. | VYNDAQEL (Drug) | Travel and Lodging | Cash or cash equivalent | $1,923.99 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/31/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | Cash or cash equivalent | $117.54 | General |
| 10/31/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $117.54 | General |
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| 10/17/2024 | PFIZER INC. | VYNDAMAX (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/10/2024 | PFIZER INC. | VYNDAQEL (Drug) | Consulting Fee | Cash or cash equivalent | $6,300.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/30/2024 | PFIZER INC. | VYNDAQEL (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM • Category: CARDIOVASCULAR | ||||||
| 09/04/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $640.79 | General |
| 09/04/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $357.68 | General |
| 08/27/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $144.66 | General |
| 08/27/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $140.16 | General |
| 08/19/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/13/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,812.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/04/2024 | PFIZER INC. | VYNDAQEL (Drug) | Travel and Lodging | Cash or cash equivalent | $404.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/30/2024 | PFIZER INC. | VYNDAQEL (Drug) | Travel and Lodging | In-kind items and services | $399.53 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/28/2024 | PFIZER INC. | VYNDAQEL (Drug) | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/19/2024 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $4,935.00 | General |
| 04/19/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | Cash or cash equivalent | $298.42 | General |
| 04/19/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | Cash or cash equivalent | $138.38 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TAFAMIDIS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $18,660 | 18 |
| T DM1 HIGH RISK EBC PTS WITH RESIDUAL INV DISEASE | Genentech, Inc. | $13,600 | 2 |
| TAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $8,090 | 9 |
| VYNDAQEL CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| VYNDAMAX CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| Twelve Pilot Study | Medtronic Vascular, Inc. | $2,750 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 705 | 1,092 | $535,690 | $112,630 |
| 2022 | 15 | 714 | 1,235 | $769,597 | $134,002 |
| 2021 | 14 | 729 | 1,193 | $637,819 | $121,951 |
| 2020 | 14 | 757 | 1,260 | $648,058 | $126,582 |
Total Patients
2,905
Total Services
4,780
Medicare Billing
$495,165
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 59 | 226 | $83,654 | $24,683 | 29.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 38 | 119 | $220,507 | $22,721 | 10.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 121 | 168 | $40,257 | $21,676 | 53.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 176 | 193 | $48,356 | $15,137 | 31.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 52 | 52 | $16,981 | $8,526 | 50.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 36 | 37 | $28,009 | $5,773 | 20.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 41 | 42 | $12,984 | $3,163 | 24.4% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 15 | 30 | $23,190 | $2,894 | 12.5% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Facility | 2023 | 51 | 82 | $22,567 | $2,595 | 11.5% |
| 93283 | Programming of dual lead implantable defibrillator system | Facility | 2023 | 32 | 36 | $11,544 | $1,730 | 15.0% |
| 93284 | Programming of multiple lead implantable defibrillator system | Facility | 2023 | 28 | 33 | $12,876 | $1,708 | 13.3% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Facility | 2023 | 21 | 35 | $4,889 | $937.04 | 19.2% |
| 93280 | Programming of dual lead pacemaker system | Facility | 2023 | 17 | 19 | $4,256 | $657.22 | 15.4% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Facility | 2023 | 18 | 20 | $5,620 | $430.74 | 7.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 42 | 228 | $422,484 | $44,696 | 10.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 54 | 206 | $75,808 | $19,387 | 25.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 112 | 155 | $44,192 | $18,774 | 42.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 171 | 196 | $55,804 | $15,581 | 27.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 69 | 69 | $21,276 | $11,197 | 52.6% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 26 | 75 | $57,975 | $7,405 | 12.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 35 | $23,723 | $6,224 | 26.2% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Facility | 2022 | 53 | 91 | $22,723 | $2,954 | 13.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 33 | 35 | $9,630 | $2,281 | 23.7% |
| 93284 | Programming of multiple lead implantable defibrillator system | Facility | 2022 | 22 | 31 | $10,854 | $1,661 | 15.3% |
| 93283 | Programming of dual lead implantable defibrillator system | Facility | 2022 | 23 | 29 | $8,096 | $1,530 | 18.9% |
About Dr. Ronald Witteles, MD
Dr. Ronald Witteles, MD is a Internal Medicine healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1285779389.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ronald Witteles, MD has received a total of $268,741 in payments from pharmaceutical and medical device companies, with $57,566 received in 2024. These payments were reported across 150 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($119,627).
As a Medicare-enrolled provider, Witteles has provided services to 2,905 Medicare beneficiaries, totaling 4,780 services with total Medicare billing of $495,165. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Cardiovascular Disease, Advanced Heart Failure and Transplant Cardiology
- Location Stanford, CA
- Active Since 02/20/2007
- Last Updated 04/26/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1285779389
Products in Payments
- VYNDAQEL (Drug) $94,402
- VYNDAMAX (Drug) $17,424
- Herceptin (Biological) $13,600
- ONPATTRO (Drug) $11,351
- DARZALEX (Drug) $1,768
- Reveal LINQ (Device) $153.02
- LOKELMA (Drug) $129.93
- WAINUA (Drug) $127.50
- AMVUTTRA (Drug) $125.00
- XARELTO (Drug) $111.39
- TEGSEDI (Drug) $93.25
- 3F (Device) $21.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Stanford
Dr. Christian Eversull, M.d, M.D
Internal Medicine — Payments: $2.9M
Internal Medicine $2.9M
Glenn Chertow, Md, MD
Internal Medicine — Payments: $1.9M
Internal Medicine $1.9M
Rahul Sharma, Md, MD
Internal Medicine — Payments: $1.0M
Internal Medicine $1.0M
Deepu Madduri, Md, MD
Internal Medicine — Payments: $749,916
Internal Medicine $749,916
Mark Pegram, M.d, M.D
Internal Medicine — Payments: $542,122
Internal Medicine $542,122
Richard Lafayette, M.d, M.D
Internal Medicine — Payments: $499,103
Internal Medicine $499,103